Recent performance snapshot

Biohaven (BHVN) has recently caught investor attention after a one-month return of 22.2%, contrasting with a past three-month total return decline of 22.4% and a one-year total return decline of 50.1%.

The recent 22.2% one month share price return, alongside a 4.8% one day gain at a share price of US$10.68, contrasts with a 50.1% one year total shareholder return decline. This suggests short term momentum after a tougher period for longer term holders.

If you are looking beyond Biohaven for more ideas in healthcare and biotech, this is a good moment to scan 35 healthcare AI stocks

With Biohaven still loss making, a market cap of about US$1.5b and a recent share price of US$10.68, the key question is whether this pullback leaves potential upside on the table or if the market is already pricing in future growth.

Preferred Price to Book Multiple of 30.9x: Is it justified?

Biohaven currently trades on a P/B of 30.9x, which is substantially higher than both the broader US biotechs industry and its closer peer group.

The P/B ratio compares a company’s market value with its book value, so a higher figure often reflects strong expectations about future assets, earnings power or both. For a loss making biopharma business with minimal revenue and a large development pipeline, it usually means investors are placing significant weight on potential future treatments rather than current financials.

For Biohaven, the current 30.9x P/B sits far above the US biotechs industry average of 2.5x and the peer average of 3.9x. This suggests that the market is assigning a very rich premium compared with sector norms. With no meaningful revenue reported and the company expected to remain unprofitable over the next three years, that premium appears to be supported mainly by confidence in the pipeline and future clinical or commercial milestones rather than near term earnings.

Result: Price to book ratio of 30.9x (OVERVALUED)

However, this premium rests on a zero revenue base and a US$738.822m net loss, so any clinical, regulatory or funding setback could quickly challenge the current story.

Next Steps

Given the mixed tone of recent performance and valuation, it makes sense to check the underlying data yourself and decide how comfortable you are with the risk profile. Before making any move, review the 4 important warning signs.

Looking for more investment ideas?

If Biohaven has you thinking differently about risk and reward, do not stop here. Use this momentum to size up other opportunities that match your style.

• Spot potential value opportunities early by scanning companies on attractive terms using the 61 high quality undervalued stocks.
• Prioritise resilience and sleep easier at night by checking out the 73 resilient stocks with low risk scores.
• Hunt for underfollowed stories with solid fundamentals through the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.